Since VK2 (GlakayR) itself is nontoxic and has been administered daily for a long time to patients with osteoporosis in Japan, the use of VK2 as a chemosensitizer for VEN via NOXA-mediated MCL-1 suppression appears to be a promising strategy. The gene discussed is MCL1; the disease is osteoporosis.